Insider Transactions in Q3 2021 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2021
|
Thomas Richard Kassberg CBO & EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
109,734
+33.63%
|
$0
$0.31 P/Share
|
|
Sep 13
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Bona fide gift
|
Direct |
819
-5.45%
|
-
|
|
Sep 08
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,336
-20.38%
|
$733,600
$100.65 P/Share
|
|
Sep 08
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,336
+16.93%
|
$396,144
$54.5 P/Share
|
|
Sep 02
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-6.06%
|
$250,000
$100.18 P/Share
|
|
Sep 02
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+5.71%
|
$137,500
$55.0 P/Share
|
|
Sep 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-6.06%
|
$250,000
$100.03 P/Share
|
|
Sep 01
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+5.71%
|
$137,500
$55.0 P/Share
|
|
Jul 06
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
375
-1.46%
|
$34,125
$91.53 P/Share
|